产品
编 号：F456273
分子式：C23H30O5
分子量：386.48
分子式：C23H30O5
分子量：386.48
产品类型
规格
价格
是否有货
5mg
436
In-stock
10mg
704
In-stock
结构图
CAS No: 7753-60-8
产品详情
生物活性：
Anecortave acetate is a potent ocular angiostatic agent. Anecortave acetate inhibits neovascularization which is induced by many different angiogenic factors, and increases plasminogen activator inhibitor-1 (PAI-1) mRNA expression. Anecortave acetate can be used to research ocular neovascular diseases.
体内研究：
Anecortave acetate (5 μl of a 10% suspension; Injected into eyes) significantly inhibits pathologic retinal angiogenesis and increases PAI-1 mRNA levels.Animal Model:Sprague-Dawley albino rats (intravitreally injected with premixed antibiotics to influence retinal vessel growth)
Dosage:5 μl of a 10% suspension of Anecortave acetate
Administration:Injected into eyes
Result:significantly inhibited pathologic retinal angiogenesis in this model, while not significantly affecting normal intraretinal vessels.Increased 6-to-9-fold PAI-1 mRNA at 1 to 3 days after injection.
Anecortave acetate is a potent ocular angiostatic agent. Anecortave acetate inhibits neovascularization which is induced by many different angiogenic factors, and increases plasminogen activator inhibitor-1 (PAI-1) mRNA expression. Anecortave acetate can be used to research ocular neovascular diseases.
体内研究：
Anecortave acetate (5 μl of a 10% suspension; Injected into eyes) significantly inhibits pathologic retinal angiogenesis and increases PAI-1 mRNA levels.Animal Model:Sprague-Dawley albino rats (intravitreally injected with premixed antibiotics to influence retinal vessel growth)
Dosage:5 μl of a 10% suspension of Anecortave acetate
Administration:Injected into eyes
Result:significantly inhibited pathologic retinal angiogenesis in this model, while not significantly affecting normal intraretinal vessels.Increased 6-to-9-fold PAI-1 mRNA at 1 to 3 days after injection.
产品资料
Copyright©2015-2024 沪ICP备2022026524号-1
沪公网安备